STS101

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

April 3, 2019

https://clinicaltrials.gov/ct2/show/NCT03901482?type=Intr&cond=Migraine&sfpd_d=14&sel_rss=new14

Conditions : Migraine; Migraine With Aura; Migraine Without Aura

Interventions : Drug: Dihydroergotamine; Drug: Placebos

Sponsor : Satsuma Pharmaceuticals, Inc.

Not yet recruiting

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482

Wed, 03 Apr 2019 12:00:00 EDT

Last Update Posted: 04/03/19 07:39AM

March 14, 2019

https://clinicaltrials.gov/ct2/show/NCT03874832?type=Intr&cond=Migraine&lupd_s=02%2F28%2F2019&lupd_d=14

Conditions : Migraine With Aura; Migraine Without Aura; Migraine

Intervention : Drug: Dihydroergotamine

Sponsor : Satsuma Pharmaceuticals, Inc.

Completed

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832

Thu, 14 Mar 2019 12:00:00 EDT

Last Update Posted: 03/14/19 09:43AM